ecropolis

Miscroscope view of Covid Cells

August 30, 2024

Effectiveness of Historical Smallpox Vaccination against Mpox Clade II in Men in Denmark, France, the Netherlands and Spain, 2022 |
Pemivibart is Less Active against Recent SARS-CoV-2 JN.1 Sublineages | U.S. Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients |
COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People | Post-acute COVID-19 Outcomes Including Participant-reported Long COVID: Amubarvimab/romlusevimab versus Placebo in the ACTIV-2 Trial

August 30, 2024 Read More »

Covid Cells

August 22, 2024

What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult | Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024 | Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study | The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger | Characterizing Long COVID in Children and Adolescents

August 22, 2024 Read More »

Covid Vaccination

August 15, 2024

Onward Virus Transmission after Measles Secondary Vaccination Failure | Single Monoclonal Antibodies Should Not be Used for COVID-19 Therapy: A Call for Antiviral Stewardship |
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort | Risk Factors for Long COVID Syndrome in Postmenopausal Women with Previously Reported Diagnosis of COVID-19 |
Long-COVID Symptom Monitoring: Insights from a Two-year Telemedicine Study

August 15, 2024 Read More »

Person receiving a COVID-19 vaccine injection

August 1, 2024

Personal Protective Effect of Wearing Surgical Face Masks in Public Spaces on Self-reported Respiratory Symptoms in Adults |
Cohort Study of Cardiovascular Safety of Different COVID-19 Vaccination Doses among 46 million Adults in England | Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years | Incidence of Diabetes after SARS-CoV-2 Infection in England |
Post-COVID-19 Respiratory Sequelae Two Years after Hospitalization |
Incidence of Hearing Loss Following COVID-19 among Young Adults in South Korea | The Effect of Long-term COVID-19 Infection on Maternal and Fetal Complications

August 1, 2024 Read More »

Covid Cells

July 24, 2024

Insights from an N3C RECOVER EHR-based Cohort Study Characterizing SARS-CoV-2 Reinfections and Long COVID |
Cost-effectiveness of COVID Rapid Diagnostic Tests for Patients with Severe/Critical Illness in Low- and Middle-income Countries: A Modeling Study |
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine |
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19 | Tracking cognitive trajectories in older survivors of COVID-19 up to 2.5 years post-infection

July 24, 2024 Read More »

Children with COVID-19

July 18, 2024

Post–Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 | Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for COVID-19 |
Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity |
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19 |
Comparative Effectiveness of Combination Therapy with Nirmatrelvir–ritonavir and Remdesivir versus Monotherapy with Remdesivir | Postacute Sequelae of SARS-CoV-2 Infection |
The Efficacy of Antivirals, Corticosteroids, and mAbs as Acute COVID Treatments

July 18, 2024 Read More »

Coronavirus Particles

July 4, 2024

Effectiveness and Safety of Molnupiravir in the Intended-Use Population: An Observational Cohort Study | The Life-saving Benefit of Dexamethasone in Severe COVID-19 is Linked to a Reversal of Monocyte Dysregulation | EEG Signatures of Cognitive Decline after Mild SARS-CoV-2 Infection: An Age-dependent Study | Tissue-based T Cell Activation and Viral RNA Persist for Up to 2 Years after SARS-CoV-2 Infection

July 4, 2024 Read More »

Receive updates about Parasites without Borders initiatives, developments, and learn more about parasites by subscribing to our periodic newsletter.


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Parasites Without Borders

Un recurso educativo integral sobre todos los aspectos de las enfermedades parasitarias y su impacto en la humanidad en todo el mundo.

Donate to Parasites Without Borders Today!

Ayude a llevar la información médica y biológica más reciente sobre enfermedades causadas por parásitos eucariotas a todos los médicos y estudiantes de medicina en los Estados Unidos.

Scroll al inicio